BioSpace News Archive

Sickle cell disease is a genetic blood disorder that causes red blood cells to form abnormally, resulting in them taking on a shape like that of a sickle. This disease is incredibly debilitating and can be fatal. For thousands of years, many have suffered from sickle cell disease with little hope of it being cured.

Tivity Health, Inc. announced that its financial results for the fourth quarter and year ending December 31, 2018, as well as financial outlook for full year 2019, will be released after market close on Tuesday, February 19, 2019, followed the same day by a conference call and live webcast scheduled for 5:00 p.m. ET.

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding ETX2514SUL for the treatment of patients with pneumonia and bloodstream infections caused by carbapenem-resistantAcinetobacter baumannii

The Massachusetts Biotechnology Council (MassBio) today announced the promotion of Kendalle Burlin O’Connell to the organization’s first-ever Chief Operating Officer

Jury rejects request for tens of millions of dollars and punitive damages

Therap Global helps organizations track progress toward the United Nations’ 2030 Agenda for Sustainable Development.

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer,

The Mundipharma network of independent associated companies today announced the launch of Pelmeg®(pegfilgrastim), a biosimilar of Neulasta® following European Commission (EC) approval in November 2018

The REGAIN consortium, led by Audion Therapeutics BV, a company dedicated to the development of therapeutics for hearing loss, today reports positive results from its Phase I multiple ascending dose, open-label safety study of the Notch Inhibitor LY3056480

Immunomic Therapeutics, Inc. announced that the company has granted Japanese animal health company, ZENOAQ an exclusive license to develop and commercialize its investigational DNA vaccine, ITI-002, for canine atopic dermatitis and other companion animal allergies.